Systemic review: Radiation therapy alone in medical non-operable endometrial carcinoma.

Détails

ID Serval
serval:BIB_2787CB42ADE8
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Systemic review: Radiation therapy alone in medical non-operable endometrial carcinoma.
Périodique
European journal of cancer
Auteur(s)
van der Steen-Banasik E., Christiaens M., Shash E., Coens C., Casado A., Herrera F.G., Ottevanger P.B.
Collaborateur(s)
European Organisation for Research and Treatment of Cancer, Gynaecological Cancer Group (EORTC-GCG)
Contributeur(s)
European Organisation for Research
ISSN
1879-0852 (Electronic)
ISSN-L
0959-8049
Statut éditorial
Publié
Date de publication
09/2016
Peer-reviewed
Oui
Volume
65
Pages
172-181
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Radiotherapy is a good option for inoperable and frail patients diagnosed with endometrial cancer. Because of the lack of large multicentre trials, a systematic review was performed in an attempt to get an overview on the feasibility and efficacy of this specific approach.
We performed a bibliographic search for articles in English or French which were published in PubMed from the start of this database in January 1969 to identify publications on radiation therapy (RT) as single treatment for localised non-operable carcinoma of the endometrium. The review was completed following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines.
Twenty-five reports containing 2694 patients treated with RT as single treatment were identified that fulfilled the selection criteria. Disease-specific survival (DSS) at 5 years was reported for a cohort of 1322 (49.1%) patients. The combined DSS for this group of patients was 78.5% (range: 68.4-92%; 95% confidence interval: 74.5-82.5). External beam radiation therapy (EBRT) combined with brachytherapy (BT) was used in 1278 patients (47.4%), BT alone in 1383 patients (51.3%), and EBRT alone in 33 patients (1.2%). The average occurrence of grade III or worse late toxicity was 3.7% for EBRT + BT, 2.8% for BT alone, and 1.2% for EBRT alone.
RT is in terms of disease control and toxicity, an acceptable option for non-surgical candidate patients. Prospective multicentre randomised or observational trials are needed to validate these results.

Mots-clé
Brachytherapy/methods, Carcinoma/radiotherapy, Disease-Free Survival, Endometrial Neoplasms/radiotherapy, Female, Humans, Prospective Studies, Radiotherapy/adverse effects, Radiotherapy/methods, Brachytherapy, Carcinoma, endometrioid, Endometrial carcinoma, Genital neoplasms, female, Intracavity radiotherapy, Radiotherapy, Uterine neoplasms
Pubmed
Web of science
Création de la notice
28/10/2016 9:42
Dernière modification de la notice
20/08/2019 13:06
Données d'usage